Company news
Aurinia Pharmaceuticals Inc news in 2024
Aurinia Pharmaceuticals Inc's news releases, calls and decks from 2024, newest first.
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
November 17, 2024
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
November 14, 2024
Aurinia to Participate in Jefferies London Healthcare Conference
November 13, 2024
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
November 6, 2024
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
November 6, 2024
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
October 29, 2024
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
October 10, 2024
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
September 23, 2024
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
September 12, 2024
Aurinia Announces Board Restructuring
September 11, 2024
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
September 4, 2024
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
July 31, 2024
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
July 18, 2024
Aurinia to Participate in Upcoming Investor Healthcare Conferences
July 1, 2024
Aurinia Announces 2024 Annual General Meeting Results
June 13, 2024
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
June 4, 2024
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
June 3, 2024
Aurinia Provides Update on Proxy Statement
June 2, 2024
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
May 29, 2024
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
May 13, 2024
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
May 8, 2024
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
May 6, 2024
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
May 1, 2024
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
April 30, 2024
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
April 29, 2024
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 15, 2024
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
April 14, 2024
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
April 8, 2024
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
February 28, 2024
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
February 14, 2024
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
February 4, 2024
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
January 4, 2024
Calls in 2024
- Aurinia Pharmaceuticals (NASDAQ:AUPH) Q3 2024 Earnings Call
Nov 7, 2024
Transcript - Aurinia Pharmaceuticals (NASDAQ:AUPH) Q2 2024 Earnings Call
Aug 1, 2024
Transcript - Aurinia Pharmaceuticals (NASDAQ:AUPH) Q1 2024 Earnings Call
May 2, 2024
Transcript - Aurinia Pharmaceuticals (NASDAQ:AUPH) Q4 2023 Earnings Call
Feb 15, 2024
Transcript